Thinly traded AtriCure (ATRC -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:
The company's Convergent procedure is unlikely to gain traction considering its poor safety profile and lack of incremental benefit compared to catheter-based procedures.
The total available market for its surgical ablation products is much smaller that it claims and is almost completely saturated.
Other approaches, real-time mapping and pulse-field ablation, are set to revolutionize catheter ablation to the detriment of Convergent and the company's core surgical devices business.
https://seekingalpha.com/news/3618422-atricure-down-9-on-kerrisdale-short-call
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.